May 7, 2020
This will be a joint initiative of the ministries of AYUSH, health, and science and technology through the Council of Scientific and Industrial Research (CSIR) with technical support from the Indian Council of Medical Research (ICMR), Union Health Minister Harsh Vardhan said.
Simultaneously, the efficacy of ayurvedic drugs yashtimadhu, combination of Guduchi and Pippali and a poly-herbal formulation (AYUSH-64) along with ashwagandha will also be evaluated as a prophylaxis and add on to standard care in mild to moderate COVID-19 patients, Secretary in the Ministry of AYUSH Vaidya Rajesh Kotecha said.
“These randomised controlled clinical trials will help us assess the benefit of these ayurvedic drugs as a preventive intervention and as an add on therapy in arresting the progression of the respiratory ailment,” Kotecha said.
An interdisciplinary AYUSH Research and Development Task Force with a group of experts under the chairmanship of Dr Bhushan Patvardhan, Vice Chairmen of University Grant Commission, has formulated clinical research protocols for prophylactic studies and add-on interventions in COVID-19 positive cases thorough review and consultative process for studying these four different interventions — ashwagandha, yashtimadhu, guduchi and pippali, and AYUSH-64.
The study will be carried out through four research councils under the Ministry of AYUSH and national institutes in 25 states and several state governments covering around five lakh people, he said.